The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | Update on the use of interferon-alfa for polycythemia vera
Richard Silver, MD, Weill Cornell Medical College, New York, NY, discusses clinical updates on the use of interferon-alpha for the treatment of polycythemia vera. Prof. Silver shares insights from key ongoing clinical trials which suggest the superiority of interferon-alfa to hydroxyurea for high-risk polycythemia vera patients with regards to JAK2 allele burden, toxicity profile, and restoration of marrow architecture. Prof. Silver also talks on the promising outcomes of an ongoing Phase II trial (NCT03003325) comparing the use of pegylated proline-interferon alfa-2b with phlebotomy-based strategies in low-risk patients. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Richard Silver, MD, has participated in speakers’ bureau with PharmaEssentia and consultancy with AbbVie.
